US2017296635A1PendingUtilityA1

Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities

58
Assignee: ATYR PHARMA INCPriority: Jun 26, 2008Filed: Jan 25, 2017Published: Oct 19, 2017
Est. expiryJun 26, 2028(~1.9 yrs left)· nominal 20-yr term from priority
Inventors:Leslie Ann GreeneRyan Andrew AdamsFei HongJi-Fu ZhaoEva Rebecka Stephanie ArmourKristi Helen Piehl
A61P 37/06A61P 37/00A61P 9/00C12N 9/93C12N 15/102C12N 9/96C12Q 1/25C12Y 601/01014A61P 29/00C07K 1/14C07K 16/40A61P 3/00A61P 25/00A61K 38/53A61P 31/00C07K 2319/00A61P 35/00
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.

Claims

exact text as granted — not AI-modified
1 - 21 . (canceled) 
     
     
         22 . A therapeutic composition, comprising a physiologically acceptable carrier and an antibody or antigen-binding fragment thereof that binds a glycyl-tRNA synthetase (GlyRS) polypeptide at amino acid residues 1-61 or 25-56 of SEQ ID NO:1. 
     
     
         23 . The therapeutic composition of  claim 22 , wherein the antibody or antigen-binding fragment thereof is at least about 95% pure. 
     
     
         24 . The therapeutic composition of  claim 22 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody. 
     
     
         25 . The therapeutic composition of  claim 22 , wherein the antibody is a humanized antibody. 
     
     
         26 . The therapeutic composition of  claim 22 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide. 
     
     
         27 . The therapeutic composition of  claim 22 , which is a sterile, freeze-dried powder. 
     
     
         28 . The therapeutic composition of  claim 22 , which is a sterile injectable solution. 
     
     
         29 . The therapeutic composition of  claim 22 , wherein the composition is buffered and comprises an isotonic agent. 
     
     
         30 . The therapeutic composition of  claim 22 , which is suitable for intravenous, intramuscular, subcutaneous, or intraperitoneal administration. 
     
     
         31 . The therapeutic composition of  claim 22 , comprising a surfactant.

Join the waitlist — get patent alerts

Track US2017296635A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.